Incyte (INCY)Officer sold ~$1.18M

~$1.18M

Approx. value · 11K sh @ $109.07

66K

Holds after · shares reported

Traded

Jan 7, 2026

Filed

Jan 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 10, 20255% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 5.0%
2. Nov 10, 2025Insider · Their largest sale since 2017Director sold ~$19.8M of INCY shares in the open market
3. Nov 17, 2025InsiderOfficer sold ~$29K of INCY shares in the open market
4. Nov 21, 2025InsiderOfficer sold ~$17K of INCY shares in the open market
5. Nov 24, 2025InsiderOfficer sold ~$62K of INCY shares in the open market
6. Dec 1, 2025InsiderOfficer sold ~$263K of INCY shares in the open market
7. Dec 2, 2025Insider · 8 days before an 8-KOfficer sold ~$2.06M of INCY shares in the open market
8. Dec 10, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately.”
9. Dec 10, 2025InsiderOfficer sold ~$531K of INCY shares in the open market
10. Dec 11, 2025InsiderOfficer sold ~$24K of INCY shares in the open market
11. Dec 16, 2025Insider · 1 personInsiders: 2 sales (~$5.3M)
12. Dec 17, 2025FDAFDA drug approval: Zynyz
13. Dec 17, 2025InsiderOfficer sold ~$420K of INCY shares in the open market
14. Dec 18, 2025InsiderOfficer sold ~$59K of INCY shares in the open market
15. Dec 19, 2025InsiderOfficer sold ~$277K of INCY shares in the open market
16. Jan 5, 2026InsiderOfficer sold ~$1.59M of INCY shares in the open market
17. Jan 7, 2026 · this disclosureInsiderOfficer sold ~$1.18M of INCY shares in the open market

What came next

1. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
2. Feb 10, 20265% stakeFelix J. Baker filed an activist stake (13D) of 15.7%
3. Feb 19, 2026InsiderOfficer sold ~$1.88M of INCY shares in the open market
4. Mar 17, 2026Insider · 8 days before an 8-KOfficer sold ~$1.76M of INCY shares in the open market
5. Mar 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately.”
6. Mar 26, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026.”
7. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
8. Mar 30, 2026FDAFDA drug approval: Zynyz
9. Apr 17, 2026Insider · 11 days before resultsOfficer sold ~$1.8M of INCY shares in the open market
10. Apr 28, 2026Company filing · Form 8-K · ResultsReported its results
11. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 6.3%
12. May 1, 2026FDAFDA drug approval: Jakafi XR

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Incyte

For Incyte, OQRO holds 23 insider filings (SEC Form 4 or Form 144) and 14 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its INCY page.

Other recent filings by Mohamed Khairie Issa, EVP, Head of US Oncology

• SEC Form 4 at Incyte (INCY)Jul 20, 2026

The full history of Mohamed Khairie Issa, EVP, Head of US Oncology is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Incyte

• SEC Form 4Sep 17, 2026
• SEC Form 4Sep 17, 2026
• SEC Form 144Sep 15, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its INCY page.